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Inhibitors targeting bacterial enzymes should not interfere with enzymes of the host, and
knowledge about structural determinants for selectivity is important for designing inhibitors
with a therapeutic potential. We have determined the binding strengths of two hydroxamate
compounds, galardin and compound 1b for the bacterial zinc metalloproteases, thermolysin,
pseudolysin and auerolysin, known to be bacterial virulence factors, and the two human zinc
metalloproteases MMP-9 and MMP-14. The active sites of the bacterial and human enzymes
have huge similarities. In addition, we also studied the enzyme-inhibitor interactions by
molecular modelling. The obtained Ki values of galardin for MMP-9 and MMP-14 and com-
pound 1b for MMP-9 are approximately ten times lower than previously reported. Compound
1b binds stronger than galardin to both MMP-9 and MMP-14, and docking studies indicated
that the diphenyl ether moiety of compound 1b obtains more favourable interactions within
the S´1-subpocket than the 4-methylpentanoyl moiety of galardin. Both compounds bind
stronger to MMP-9 than to MMP-14, which appears to be due to a larger S´1-subpocket in the
former enzyme. Galardin, but not 1b, inhibits the bacterial enzymes, but the galardin Ki val-
ues were much larger than for the MMPs. The docking indicates that the S´1-subpockets of
the bacterial proteases are too small to accommodate the diphenyl ether moiety of 1b, while
the 4-methylpentanoyl moiety of galardin enters the pocket. The present study indicates that
the size and shape of the ligand structural moiety entering the S´1-subpocket is an important
determinant for selectivity between the studied MMPs and bacterial MPs.
Introduction
Proteases are enzymes that cleave peptides and proteins at their N- or C-terminal ends (exo-
peptidases) or within the polypeptide chain (endopeptidases). They are important for all
organisms, and it is estimated that there are more than 66000 different proteases [1, 2]. In
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microorganisms, proteases are important for generation of nutrition, invasion into host organ-
isms as well as growth and survival [3–9]. In vertebrates, they are involved in the regulation of
various physiological processes including cell growth, cell signalling, blood pressure, coagula-
tion, angiogenesis, reproduction, wound repair, hemostasis and homeostasis [2, 10–14]. In
humans, diseases are often associated with dysregulation of one or several proteases [10, 11,
15–18] and several proteases are important targets for therapeutic intervention [19–22].
Proteases are divided into classes or clans based on residues involved in the catalytic reaction
[2, 23–25]. One of these classes is the metalloproteases (MPs), where the catalytic metal most
often is a zinc ion [23, 24]. The bacterial zinc-MPs thermolysin, pseudolysin and auerolysin are
secreted by various types of bacteria including bacillus thermoproteolyticus, pseudomonas aeru-
ginosa and staphylococcus aureus, and act as virulence factors [26]. These proteases belong to
the M4 family of proteases. Thermolysin is one of the most studied proteases, and has become a
model enzyme for the M4 family [26]. In humans, one of the most studied MP families is the
matrix metalloproteases (MMPs) also called matrixins [15]. They belong to the M10 family, and
in humans there are 23 different MMPs. Seven of them contain a transmembrane domain or a
glycosylphosphatidyl-inosityl (GPI) moiety which links them to the cell membrane, while the
other sixteen MMPs are secreted enzymes [15]. The most studied among the membrane linked
is MT1-MMP (MMP-14), while MMP-9 (gelatinase B) is the most studied among the secreted
MMPs [18, 27]. The reason for the intense studies of MMPs is that they are involved in a large
variety of physiological processes and that they are dysregulated in a number of different malig-
nant disorders including various types of cancer, arthritis, osteoarthritis, diabetes, cardiovascu-
lar-, eye-, brain- and nervous system diseases [15, 18].
Thermolysin, pseudolysin and auerolysin are secreted proteases classified into the clan glu-
zincins, i.e. their catalytic zinc ion is bound to the protein through two histidines and a gluta-
mate (HEXXH+E) [23, 24, 26]. The fourth zinc ligand is a water molecule that is polarized by
the glutamic residue next to the first histidine that binds the catalytic zinc. The catalytic sites of
thermolysin and pseudolysin have been extensively studied through X-ray crystallography
with various inhibitors bound and several structures are deposited in the protein database
(PDB). However, for auerolysin only one X-ray structure of the free enzyme is available.
Like the majority of the MMPs, both MMP-14 and MMP-9 contain an N-terminal signal
peptide followed by a pro-domain with the conserved PRCGV sequence to keep the enzyme
in a latent state. This is followed by a catalytic domain linked to the C-terminal hemopexin
like domain (HPX) through a hinge or linker region which varies in length and structure
between the MMPs [15]. The HPX domain in MMPs is involved in complex formation with
other biological molecules, activation and substrate specificity [15, 28, 29] and the 3D struc-
ture shows that this domain adopts a four bladed β-propeller where blade I is connected to
blade IV through a disulphide bridge [30]. Fig 1A shows a schematic drawing of a general
MMP structure with its domains and modules. MMPs belong to the clan metzincins and the
catalytic zinc ion is bound to the protein through the three histidines of the segment
(HEXXHXXGXXH/D+M) [23, 24]. In their inactive pro-form, the fourth zinc ligand is the
cysteine of the PRCGV motif of the pro-domain [31, 32]. MMP-14 also contains a type 1
trans-membrane domain C-terminally linked to the HPX domain. At the end of the pro-
domain, it contains a basic motif (RX(K/R)R). This motif is recognized by the intracellular
serine protease, furin [15]. Hence MMP-14 is activated in the endoplasmatic reticulum and
transported to the cell membrane as an active protease lacking its pro-domain, with the
active site located in the extracellular environment [15]. MMP-9 on the other hand lacks the
(RX(K/R)R) motif and is secreted from cells as an inactive pro-enzyme. This enzyme is
unique among the MMPs as it contains a long and heavily O-glycosylated hinge region, also
called the OG-domain. In addition, both MMP-9 and MMP-2 contain a large insert in the
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catalytic site, i.e. three fibronectin II-like motifs (FnII) which is important for the activity
against some macromolecular substrates, such as denatured collagen (gelatin) [27, 33–38].
However, the FnII repeats have no effect on the enzymes’ processing of small chromogenic
peptide substrates or small inhibitors that only interact with the active site [34]. The long
hinge region of MMP-9 is very flexible as shown previously by small angle X-ray crystallog-
raphy combined with atomic force microscopy and is probably the reason for that the X-ray
structure of the full length MMP-9 has not been solved [39]. To what extent the hinge region
and the bound sugars, as well as the HPX domain of MMP-9, interact with the catalytic
domain is not known. Even though these two domains did not have an effect of MMP-9’s
cleavage of some biological macromolecular substrates [40], it cannot be excluded that they
are involved in the cleavage of other macromolecular substrates or small chromogenic sub-
strates as well as binding of inhibitors to the catalytic site. MMP-9 can be activated in the
extracellular environment by various naturally occurring proteases such as trypsin, kalli-
krein, MMP-2 and MMP-3. In addition, MMP-9 is also activated by organic mercurial com-
pounds such as p-aminophenylmercuric acetate (APMA) and by bacterial proteases such as
thermolysin and pseudolysin [32]. Various activators cleave the MMP-9 pro-domain at dif-
ferent positions resulting in enzyme structures with different N-terminals [32]. In addition,
both protease activation and APMA induced auto-activation are also accompanied to vari-
ous extents with further truncation of the enzyme by cleavage of the HPX domain and in
some cases of the OG-domain [41–45]. Binding of inhibitors to the active site of MMP-9
and MMP-14 have been extensively investigated both by kinetic and X-ray crystallography
studies [46–54]. For both, inhibitor binding is most often studied by using the recombinant
Fig 1. Domain structure of MMPs (A) and schematic representation of galardin and compound 1b (B). All MMPs contain a
signal peptide (cleaved off in the endoplasmatic reticulum), a pro-peptide domain and a catalytic domain. In addition, most MMPs
contain a linker (hinge-region) and a hemopexin (HPX) like domain. The hinge region in MMP-9 differs from the other MMPs as it
is longer and heavily O-glycosylated, and therefore also called the OG-domain. Three secreted (MMP-11, -21, -28) and all
membrane-anchored MMPs have a basic RX[K/R]R motif at the C-terminal end of their pro-domain. This motif can be cleaved
inside the cells by furin-like proteases. The two gelatinases (MMP-2, -9) contain three fibronectin II like repeats (FnII module) in
their catalytic domain, located N-terminal to the catalytic Zinc-binding site. Four of the six membrane-type (MT)-MMPs are
anchored to the cell membranes through a type I transmembrane domain and the other two through a glycosylphosphatidylinosityl
(GPI) moiety.
https://doi.org/10.1371/journal.pone.0200237.g001
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catalytic domains of MMP-14 and MMP-9. In the latter enzyme, the fibronectin II-like
module in the catalytic site is lacking in most of the structures deposited in the PDB.
Many bacterial proteases like thermolysin, pseudolysin and auerolysin are virulent factors
and hence putative drug targets [5–8, 55]. However, it is important that drugs targeting the
bacterial enzymes not interfere with the function of the human MPs. Our focus for some time
has been on MP inhibitors [56, 57]. By studying the binding of various inhibitors to bacterial
and human MPs, we are aiming to obtain information about similarities and differences in the
active site of these enzymes that can be used in the development of compounds that bind spe-
cifically to the bacterial enzymes. In the present work we are studying the binding of two
hydroxamate containing compounds, galardin and compound 1b (Fig 1B) to thermolysin,
pseudolysin and auerolysin, and to the human MMP-9 and MMP-14. Galardin is a well stud-
ied compound that binds strongly to several MMPs including MMP-9 and MMP-14 as well as
to thermolysin and pseudolysin [58–60]. Compound 1b was developed by Moriyama and col-
leagues [61] and is an aza-sugar based hydroxamate that has been shown to bind strongly to
MMP-1, MMP-3, MMP-9 and TACE, but have not been tested against MMP-14 or bacterial
MPs. In order to assure an accurate comparison between the enzymes and between compound
1b and galardin binding, we have thoroughly retested these compounds under the same meth-
odological conditions against thermolysin, pseudolysin, MMP-14 and against differently acti-
vated full length MMP-9 isolated from THP-1 cells and recombinant human full length
proMMP-9 produced in Sf9 insect cells. The difference between native MMP-9 and recombi-
nant MMP-9 produced in Sf9 insect cells is the extent of glycosylation of the hinge region [40].
As the N-terminal residue of activated MMPs may affect inhibitor binding as previously seen
for APMA, MMP-14 and trypsin-activated MMP-2 [62], MMP-9 was activated with three dif-
ferent activators (trypsin, MMP-3 (catalytic domain) and APMA) that give different N-termi-
nal residues. Trypsin and MMP-3 are physiological activators of proMMP-9, and the small
amount of TIMP-1 present in the purified proMMP-9 from various cells such as THP-1 has
no or limited effects on the trypsin induced activation of proMMP-9, while in contrast the acti-
vation induced by other MMPs and APMA will be affected [42, 43, 63]. During mercury poi-
soning, the presence of mercury ions can result in an uncontrolled activation of proMMPs in
the victim. In addition, we have performed molecular modelling studies of the two compounds
interaction with the active site of the five enzymes. Comparing binding modes obtained by
docking with the experimentally obtained binding strengths increases the understanding of
residues and structural motifs important for binding and selectivity.
Materials and methods
Materials
TRIS, DMSO and CaCl2·2H2O and human recombinant MMP-3 catalytic domain were
from Merck (Darmstadt, Germany). EDTA and 2-Methoxy-2,4-Diphenyl-3(2H)-Furanone
(MDPF) were from Fluka (Buchs, Switzerland). Acrylamide, Commassie Brilliant Blue G-
250 and Triton X-100 were from BDH (Poole, UK). RPMI 1640, streptomycin, penicillin,
phorbol 12-myristate 13-acetate (PMA), Hepes, Brij-35, SDS, NaCl, p-aminophenylmercu-
ric acetate (APMA), trypsin, soybean trypsin inhibitor (SBTI), Tween-20 and gelatin were
purchased from Sigma (St Louis, MO, USA). Magnetic trypsin beads (Mag-Trypsin) were
purchased from Takara (Gothenburg, Sweden). Gelatin-Sepharose, Q-Sepharose, Sephadex
G-50 (fine), were from GE-Healthcare (Uppsala, Sweden). Unlabelled molecular weight
standards were from BioRad (Richmond, CA, USA), while the SpectraTM Multicolor High
Range Protein ladder was from Pierce Biotechnology (Rockford, IL, USA). Magic Marker
molecular weight standards, NuPAGE Novex 4–12% BisTris gels and Sf9 insect cells were
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from Invitrogen (Carlsbad, CA, USA). Western Blotting Luminol reagent was from Sancta
Cruz (Santa Cruz, CA, USA). Rabbit anti-rat MMP-9 polyclonal antibody (also detect
mouse and human MMP-9) was obtained from Chemicon International Inc. (Temecula,
CA, USA). HRP-conjugated goat anti-rabbit secondary antibody was from Southern Bio-
tech (Birmingham, AL, USA). Galardin (Gm6001), pseudolysin, thermolysin and recombi-
nant MMP-14 (catalytic domain) were from Calbiochem (San Diego, CA, USA). SpectraTM
Mulitcolor High Range Protein Ladder was from Pierce (Rockford, IL, USA). Fetal bovine
serum was from Biochrom AG (Berlin, Germany). Auerolysin was from BioCentrum Ltd
(Kraków, Poland). The chromogenic substrates Mca-PLGLDpaAR-NH2 (ES001) and Mca-
RPPGFSAFK(Dnp)-OH (ES005) were from R&D Systems, Inc (Minneapolis, MN, USA).
Azasugar-based MMP-inhibitor 1b was a kind gift from Dr. Hideki Moriyama (Dept. Drug.
Disc. Res., Carna Bioscience Inc., Kobe, Japan). Human MMP-9 (recombinant catalytic
domain) was from AnaSpec (Fremont, CA, USA). Vivaspin columns with a 10 and 30 kDa
cut-off were from Sartorius Stedim Biotech GmbH (Goettingen, Germany). Imperial blue
protein stain was from Thermo Scientific (Rockford, Il, USA).
Production and purification of proMMP-9 from THP-1 cells
The human leukemic monocyte cell-lines THP-1 was a kind gift from Dr. K. Nilsson, Depart-
ment of Pathology, University of Uppsala, Sweden. The cells were cultured in RPMI 1640
medium with 10% fetal bovine serum, 50 μg/ml of streptomycin, and 100 units/ml of penicillin.
To produce proMMP-9, the cells were washed 3 times in serum-free medium and then cultured
for 72 h in serum-free RPMI 1640 medium containing 0.1 μM PMA as described earlier [64].
Conditioned medium was harvested, loose cells were pelleted by centrifugation at 1200 rpm
(200g) for 10 min. ProMMP-9 was first separated from Chondroitin sulphate proteoglycans
(CSPG) and proMMP-9CSPG heteromers by Q-Sepharose anion exchange chromatography
and then purified by Gelatin-Sepharose affinity chromatography as described previously [65].
Production and purification of recombinant human full length proMMP-9
from Sf9 insect cells
The cDNA encoding human preproMMP-9 (accession number: BC006093.1) cloned into the
pReceiver-M02 vector (catalogue number: EX-F0125-M02) was purchased from GeneCopoeia
(Rockville, MD). The cDNA was flanked by InvitrogenTM GatewayTM attB-sequences (Invitro-
gen, Thermo Fisher Scientific Inc.) and was transferred to pDONR221 using Gateway1 BP
Clonase1 II Enzyme mix (Invitrogen, Thermo Fisher Scientific Inc.) and subsequently to
BaculoDirectTM Linear DNA (catalogue number: 12362013) using Gateway1 LR Clonase1
II Enzyme mix preserving the endogenous MMP-9 stop codon. Baculoviruses were produced
using Sf9 cells according to the protocol of the BaculoDirectTM Baculovirus Expression System.
The P3 viral stock was used for production of preproMMP-9 in Sf9 cells in suspension.
Thirty ml of serum containing medium from baculovirus infected Sf9 cells was applied to a
1 ml column of Gelatin-Sepharose pre-equilibrated with 0.1 M Hepes buffer pH 7.5 containing
5.0 mM CaCl2. After collecting the pass-through medium, the column was first washed with
10 column volumes of 0.1 M M Hepes buffer pH 7.5 containing 5.0 mM CaCl2 and 1.2 M
NaCl. This was followed by a new wash with 30–40 column volumes of 0.1 M Hepes buffer pH
7.5 containing 5.0 mM CaCl2. Bound proMMP-9 was eluted with a buffer containing 0.1 M
Hepes pH 7.5, 5.0 mM CaCl2 and 7.5% DMSO. The eluted material was concentrated and
depleted of DMSO (end [DMSO] less than 0.02%) using a spin column with a 10 kDa cut-off.
The amount of proMMP-9 in the sample was determined spectrophotometrically at 280 nm
using the extinction coefficient ε280nm = 114.36 mM
-1cm-1 [66]. The purified sample was
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applied to SDS-PAGE (NuPAGE Novex 4–12% Bis-Tris gels). These gels were either further
applied to Western blotting (using a polyclonal antibody against proMMP-9) or stained with
Imperial blue where bands were cut out and sent to MS analysis at the Tromsø University Pro-
teomics Platform (TUPP). Purified samples were also applied to Gelatin zymography.
Activation of proMMP-9
Activation of proMMP-9 through treatment of APMA (auto-activation), MMP-3 or trypsin
results in a balance between activation and degradation of the enzyme and hence it is impor-
tant to stop the process when the activation is at its maximum and not to allow the degradation
process to go too far.
Activation of proMMP-9 from THP-1 cells was achieved by limited proteolysis with trypsin
as described previously, and the activation was stopped by adding soybean trypsin inhibitor
(SBTI) [67, 68].
The purified recombinant full length human proMMP-9 from Sf9 cells was activated by 1
mM of APMA at 37˚C, MMP-3 (catalytic domain) at 37˚C and trypsin covalently linked to mag-
netic beads (Mag-Trypsin) at room temperature (approximately 23˚C). Activation with APMA:
Briefly, 55 μl 1.0 mM APMA was added to 500 μl of proMMP-9 (4.6 μM). At various time points,
1.0 μl of this mixture was added to 89 μl assay buffer (0.1 M Hepes pH 7.5 containing 10 mM
CaCl2, 0.005% Brij-35) and 10 μl 100 μM Mca-PLGLDpaAR-NH2. The initial rate of the reaction
was determined as described under for the determination of kinetic coefficients. When it was
estimated that maximal activation has occurred, the activation was stopped by adding 10 mM
EDTA. Thereafter, EDTA and APMA were removed from the activated enzyme by applying the
enzyme mixture to a spin column with a 10 kDa cut-off and washed with the assay buffer. Acti-
vation withMag-Trypsin: Briefly, 200 μl Mag-Trypsin was first washed with 5x1 ml of assay
buffer and finally 200 μl of the same buffer were added to the beads. Then 200 μl of Mag-Trypsin
was mixed with 200 μl of proMMP-9 (4.6 μM), and at various time points 0.5 μl of this mixture
was added to 89.5 μl of the assay buffer and 10 μl substrate and the initial rate determined as
described above. At the estimated maximal activation, Mag-Trypsin was separated from the
active MMP-9 using a strong magnet and the activated MMP-9 was thereafter applied to a spin
column with a 30 kDa cut-off and washed with assay buffer resulting in 125000-fold dilution of
contaminating peptides. Activation withMMP-3 (catalytic domain): Briefly, 200 μl proMMP-9
(4.6 μM) was mixed with 200 μl of MMP-3 (0.05 μM) in assay buffer, and at various time points
0.25 μl of the mixture was added to 89.8 μl of assay buffer and 10 μl substrate and the initial rate
determined as described above. When it was estimated that maximal activation has occurred,
the activation was stopped by adding 10 mM EDTA. Thereafter, the activated MMP-9 was sepa-
rated from MMP-3 by purification on a Gelatin-Sepharose column as described above, with the
exception that the buffer also contained 10 mM EDTA at all washing steps and in the elution
step. EDTA and DMSO were removed from the activated enzyme by applying the enzyme mix-
ture to a spin column with a 30 kDa cut-off and washing with the assay buffer. Various dilutions
of activated proMMP-9 were used for the detection of kinetic coefficients.
Gelatin zymography
SDS-substrate PAGE was done as described previously [69] with gels (7.5 cm x 8.5 cm x 0.75
mm) containing 0.1% (w/v) gelatin in both the stacking and separating gel, 4 and 7.5% (w/v)
of polyacrylamide, respectively. Gelatinase activity was evident as cleared (unstained) regions.
Real-time gelatin zymography was performed as described previously for standard gelatin
zymography [65, 69]. The exception was that 0.1% (w/v) MDPF-fluorescent labelled gelatin
was incorporated in the 7.5% SDS-PAGE separating gel instead of 0.1% (w/v) unlabelled
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gelatin. The fluorescent dye 2-methoxy-2,4-diphenyl-3(2H)-furanone was used to label gelatin
to give MDPF-gelatin as described previously [70]. The main difference between normal gela-
tin zymography and real-time gelatin zymography is that in real-time zymography, the gel is
not stained and hence it is possible to follow the degradation of the gelatin in real time without
staining. Gelatinase activity was evident as dark bands against the undegraded fluorescent
background.
Western blotting
Purified proMMP-9 from THP-1 cells and recombinant full length human proMMP-9 from
Sf9 cells with and without 0.1 M DTT were electrophoresed on SDS-polyacrylamide gel
(NuPAGE Novex 4–12% Bis-Tris gels) and electroblotted to a polyvinyl difluoride membrane.
After blockage of non-specific binding sites with non-fat milk in TBS-T (150 mM NaCl, 0.25%
Tween-20, 20 mM Tris-HCL, pH 7.4), blots were incubated for 1 h at room temperature with
primary rabbit polyclonal antibody against human MMP-9. After washing, the blots were
incubated for 1 h at room temperature with an HRP-conjugated goat anti-rabbit secondary
antibody. The Blots were thereafter washed with TBS-T 3 x 5 min before visualization using
Western Blotting Luminol reagent. The intensity of immunoblot bands was measured using a
Luminescent Image Analyzer LAS-3000 with MultiGauge software version 3.0 (Fujifilm,
Tokyo, Japan).
Determination of kinetic coefficients
To determine the kinetic and inhibitor kinetic coefficients Km, and Ki, initial rate experiments
were performed using a Perkin Elmer LS 50 Luminescence spectrometer and the FL WinLab
Software Package (Perkin Elmer). The reactions were followed for one minute and during that
time 600 data points were collected. The excitation and emission wavelengths for the two fluo-
rescence quenched MMP peptide substrates, McaPLGLDpaAR-NH2 and Mca-RPPGFSAFK
(Dpn)-OH were; λex = 320 nm, λem = 405 nm and a slit width = 10 nm at both wavelengths.
All assays were performed at 37˚C in an assay buffer of 0.1 M Hepes pH 7.5, 0.005% Brij-35, 10
mM CaCl2 and a total assay volume of 100 μl.
Km determination. Initial rates were determined with McaPLGLDpaAR-NH2 and Mca-
RPPGFSAFK(Dpn)-OH concentrations ranging from 0.5 to 10.0 μM, higher substrate concen-
trations resulted in quenching. The Km value was calculated from non-linear regression of the
Michaelis-Menten equation using the Enzyme kinetic module in GraphPad Prism 5.
Ki determination. A fixed substrate concentration of 5.0 μM and / or 10 μM and a fixed
enzyme concentration along with varying concentrations of potential inhibitor were used to
determine the inhibitory capacity of the two compounds. From a dose response plot, vi/v0 vs
the concentration of inhibitor [I], Eq (1) was used to determine the IC50 values for competitive
inhibitors with Ki > 10 times the concentration of active enzyme in the assay ([E]) where vi
and v0 represents the initial rate activity in the presence and absence of inhibitor (I), respec-
tively. For a competitive inhibitor, the IC50 value equals Ki(1+[S]/Km). For tight binding com-
petitive inhibitors (Ki [E]), the values of Ki and [E] were obtained by both a dose response
plot (vi/v0 against [I]) using the Morrison equation [71] (2) and through the linear Henderson
Plot [72] (Eq 3). For tight binding inhibitors, the enzyme was pre-incubated for 15 min at
37˚C in the presence of inhibitor and the reaction was started by the addition of substrate.
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Ninety-six well plates and a Spectra Max Gemini EM Plate Reader controlled by the com-
puter program Soft Max Pro version 4.3 (Molecular Devices) were used to obtain the binding
strength of galardin for thermolysin and pseudolysin. Thermolysin (0.22 nM) and psudolysin
(0.26 nM) were pre-incubated with galardin for 15 min at 37˚C. The final galardin concentra-
tions in the assays varied from 2.4210−11 to 2.4210−5 M. The enzymatic reaction was started
by the addition of Mca-RPPGFSAFK(Dpn)-OH (4 μM in assay), and the initial rate of the
reaction was followed for 30 min at 37˚C using the same wavelengths as with the Perkin Elmer
fluorimeter as described above. The IC50 values were determined from a dose response plot vi/
v0 vs log [Inhibitor] as described previously [56].
Docking and scoring
Galardin and compound 1b were docked using the Internal Coordinate Mechanics (ICM) soft-
ware version 3.8–4 [73]. The compounds were docked into MMP-9, thermolysin and pseudoly-
sin using several X-ray structures of these enzymes in complex with inhibitor. The following
structures in the PDB-database were used: MMP-9; 2ovz, 4xct, 5cuh, 4h3x, thermolysin; 5dpe,
1pe5, pseudolysin; 1u4g, 3dbk. The binding modes of the inhibitors in the X-ray complexes
were used to define the binding pocket in the docking process. However, X-ray structure com-
plexes with small molecular inhibitors were not available for MMP-14 and auerolysin. For
MMP-14 we used an X-ray structure of the catalytic domain of MMP-14 in complex with the
tissue inhibitor of metalloproteinase-2 (TIMP-2) (PDB ID: 1bqq). Two strategies were used for
identifying the binding pocket. 1: The MMP-14—TIMP-2 X-ray complex were superimposed
with the MMP-9 structure in complex with an inhibitor (PDB ID: 5cuh), and the inhibitor of
MMP-9 was used to define the binding pocket in MMP-14. 2: The ICM-pocket finder was used
to identify the binding pocket. Both strategies gave similar results. For auerolysin the inhibitor-
free X-ray structure (PDB ID: 1bqb) was used for docking. The structure was superimposed
with the thermolysin-inhibitor complexes (PDB ID: 5dpe) and (PDB ID: 1pe5) and the inhibitor
in these complexes were used to define the binding pocket. Crystallographic water molecules
and co-crystallized small molecule inhibitors (MMP-9, thermolysin, pseudolysin) were removed
and hydrogen atoms were added and optimized using the ECEPP/3 force field of ICM. Galardin
and compound 1b were built using ICM and minimized before docking. A grid map that
included the active site amino acids within 5Å of co-crystallized ligand was calculated, and
semi-flexible docking with flexible ligands was performed. Three parallel docking simulations
were performed and the best-scored from the parallels was selected as the best orientation. The
ICM virtual ligand screening (VLS) scoring function was used for scoring. The compounds
were docked both with neutral and charged hydroxamate group.
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Statistical analysis
To compare the obtained Ki values for the two compounds to the various MPs, a pairwise com-
parison was obtained by the t-test in SigmaPlot (SPSS Corp. Chicago, IL,USA).
Results and discussion
In the present study, enzyme kinetics and molecular modelling have been used to elucidate the
binding of two hydroxamate compounds to the human zinc MPs MMP-9 and MMP-14 and
the bacterial zinc MPs thermolysin, pseudolysin and auerolysin. The bacterial enzymes are
secreted virulence factors, and inhibitors of these enzymes may weaken the pathogen and be a
putative therapeutic strategy against bacterial infections. However, such inhibitors should not
interfere with the substrate degradation of MMPs and other endogenous zinc MPs of the
infected host. Knowledge about the structural determinants for selectivity is therefore
important.
Synthesis, purification and activation of proMMP-9
ProMMP-9 was purified from conditioned medium of PMA stimulated THP-1 cells by first pass-
ing the medium through a Q-Sepharose column to remove chondroitin sulphate proteoglycans
(CSPG) and CSPG associated proMMP-9 (proMMP-9CSPG) from free proMMP-9 [65]. The
pass through fraction from this column contained free proMMP-9, free TIMP-1, TIMP-1 linked
to proMMP-9 and other proteins that was applied to a Gelatin-Sepharose column and eluted
with 10% DMSO as described earlier [65]. This gave rise to two bands in SDS-PAGE under
reducing conditions, a major band at 92 kDa (proMMP-9) and a minor band at 28 kDa (TIMP-
1) (Fig 2A). TIMP-1 does not bind to the Gelatin-Sepharose column, but TIMP-1 binds through
its C-terminal domain to the C-terminal HPX-domain of proMMP-9 [42, 63, 74, 75] and hence
purified proMMP-9 from THP-1 cells will always contain some TIMP-1. The bound TIMP-1
has its N-terminal domain free, the domain that interacts with the active site in MMPs and inhib-
its the activity. Hence, the presence of proMMP-9TIMP-1 complexes will affect the activation of
proMMP-9 by other active MMPs such as MMP-3. TIMP-1 binds to the active site of these
MMPs and form ternary proMMP-9TIMP-1MMP and MMP-9TIMP-1MMP complexes [63,
74]. The presence of TIMP-1 will not interfere with trypsin during the activation of proMMP-9,
but the inhibitor will bind to the active site of the activated MMP-9. TIMPs are slow, tight-bind-
ing reversible inhibitors with dissociation constants in the pico-molar region and low dissocia-
tion rates of the formed complex [32, 76]. A detailed study of the binding of TIMP-2 to MMP-2
revealed a dissociation constant (Ki) of 0.6 fM and a rate constant for the dissociation of the
MMP-2•TIMP-2 complex of 2x10-8 s-1, i.e. a half-life of approximately 1 year [77]. Similar
detailed studies have not been performed for the binding of TIMP-1 to the full length MMP-9,
and reliable Ki values could not be obtained with conventional methods due to the strong bind-
ing (low pico-molar region) [78]. The level of MMP-9 activity depends on the amount of TIMP-
1 compared to the amount of active MMP-9. With such tight complexes and extremely slow dis-
sociation rates it is fair to assume that the presence of TIMP-1 in the MMP-9 preparation will
not affect the Km value for a substrate or the Ki value of an inhibitor compared to an enzyme
preparation without TIMP-1 present. Trypsin activation gave rise to a main active form of
MMP-9 with a molecular size of approximately 84 kDa, and three minor bands of lower molecu-
lar size ranging between 62–80 kDa (Fig 2B). Previously it has been shown that trypsin activated
MMP-9 has lost the pro-domain and has F107 (sequence numbering includes the pre-sequence
of 19 amino acids) as its N-terminal amino acid residue, and hence the zinc binding motif
(97-PRCGVPD) has been removed [32]. The purified proMMP-9 was also treated with 1 mM
APMA at 37ºC up to 24h. Zymography revealed that most of the 92 kDa pro-form of MMP-9
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had been converted to an 84 kDa form, but no activity could be detected by the rate assay (data
not shown). APMA activated MMP-9 has an intact zinc binding motif (97-PRCGVPD) in the
pro-domain with M94 (sequence numbering includes the pre-sequence of 19 amino acids) as its
Fig 2. Purification and activation of proMMP-9. (A) Imperial stained SDS-PAGE showing the purity of purified recombinant
human full length proMMP-9 expressed in Sf9 cells (rproMMP-9) and of proMMP-9 purified from THP-1 cells (proMMP-9) as
described in the Materials and Methods section. PT is the pass through fraction from Gelatin-Sepharose Chromatography of the
recombinant enzyme, and 4 times more protein was loaded to the gel in the lanes labelled PT(2) compared to the lanes labelled PT
(1). Std. 1 is the molecular size marker SpectraTM Mulitcolor High Range Protein Ladder and sb is sample buffer. Prior to
electrophoresis, samples were either treated (+) or not treated (-) with DTT. Gelatin (B-D) and real-time gelatin (E) zymography of
purified proMMP-9, trypsin activated (MMP-9) proMMP-9 from THP-1 cells, purified rproMMP-9, AMPA (rMMP-9(A)), trypsin
(rMMP-9(T)) and MMP-3 (rMMP-9(M3)) activated recombinant proMMP-9. Std.2 in (B-E) is a mixture of proMMP-9 from THP-
1 cells and proMMP-2 from human skin fibroblasts. Std. 3 is the 37 kDa catalytic domain of human MMP-9.
https://doi.org/10.1371/journal.pone.0200237.g002
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N-terminal amino acid residue [32, 41, 43, 45, 79, 80]. The lack of activity is expected, as the
enzyme in addition must be C-terminally truncated in order to be active [41, 42, 74].
TIMP-1 free recombinant full length human proMMP-9 was expressed in baculovirus
infected Sf9 cells and purified from the serum-containing medium in a one-step procedure
using a Gelatin-Sepharose column. This gave rise to three bands in non-reducing SDS-PAGE
(Fig 2A) and gelatin zymography (Fig 2C), a band at 205 kDa and two bands at 87 and 83 kDa.
SDS-PAGE under reducing and non-reducing conditions (Fig 2A) revealed that the band of
205 kDa was either a homodimer or a homotrimer as recently shown by Vandooren et al. 2015
[81] and Western blotting along with mass spectroscopy (MS) confirmed that all three bands
were proMMP-9 (data not shown). The slightly lower molecular size of the recombinant
proMMP-9 compared to the native proMMP-9 is most likely due to difference in glycosylation
of the hinge region [40]. APMA activation of purified recombinant proMMP-9 in the presence
of 10 mM of CaCl2 resulted in a main form of active MMP-9 with a molecular size of 54 kDa
and three minor forms with molecular sizes of 61, 49 and 45 kDa (Fig 2C). Previously it has
been shown that APMA activated MMP-9 has an intact zinc binding motif (97-PRCGVPD) in
the pro-domain with M94 (sequence numbering includes the pre-sequence of 19 amino acids)
as its N-terminal amino acid residue and parts of the HPX-domain removed [32, 41, 43, 45, 79,
80]. Mercury ion induced auto-cleavage of the MMP-9 HPX domain occurred between E687
and L688 in the end of blade 4 and between Ala526 and Glu527 in the beginning of blade 1
[45]. A disulphide bridge link between C516 and C704 link blade 1 and blade 4 [27, 30]. This
suggests that in the 54 kDa active rMMP-9, almost the entire HPX domain is removed, but
with the last amino acids in the HPX C-terminal domain (L688—D707) retained linked to the
processed enzyme through the disulphide bridge between C516 and C704. Previously it was
suggested that the presence of Ca2+ resulted in C-terminal truncation and a conformational
change that unblocked the catalytic site and hence resulted in an enzyme with full enzymatic
activity [79].
Trypsin activation of the purified recombinant proMMP-9 resulted in a zymography pat-
tern similar to the APMA activated enzyme (Fig 2D), with a main form of active MMP-9 with
a molecular size slightly larger than 54 kDa. Thus, trypsin induced activation of the recombi-
nant proMMP-9 resulted in both the removal of the N-terminal pro-domain as well as large
parts or almost the entire C-terminal HPX-domain similar to the APMA activated enzyme.
As for the trypsin induced activation of the recombinant proMMP-9, MMP-3(catalytic
domain) induced activation also resulted in a combination of N- and C-terminal truncation of
the recombinant proMMP-9 (S1 Fig). This is in agreement with previous reports on MMP-3
induced activation of proMMP-9 [43, 80]. The fully MMP-3 activated MMP-9 (rMMP-9(M3))
after removal of MMP-3, contaminating peptides, EDTA and DMSO, has a major band at
approximately 54 kDa, and two minor bands with lower molecular size (Fig 2E). As for the
APMA and trypsin activated MMP-9, the MMP3 activated form also lacks large parts or the
entire C-terminal HPX-domain. Previously it was shown that MMP-3 and trypsin-activated
MMP-9 has identical N-terminal residue, F107 [32].
Km determination
In order to study the binding strength of inhibitors to an enzyme, it is first necessary to deter-
mine the enzyme’s Km value for the substrate under the conditions used to study inhibitory
binding. The quenched fluorescence substrate Mca-PLGLDpaAR-NH2 was used for the stud-
ies with MMP-9 and MMP-14. For trypsin activated MMP-9 from THP-1 cells a Km value of
3.0 ± 0.7 μM was obtained, while for APMA, trypsin and MMP-3 activated recombinant
human MMP-9 (rMMP-9(A), rMMP-9(T) and rMMP-9(M3)) Km values of 3.2 ± 0.2, 3.1 ± 0.4
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and 4.5 ± 0.4 μM, respectively, were obtained. Thus, there was no significant variation in the
obtained Km values in spite of differences in their N- and C-terminal amino acid residues. This
is in contrast to trypsin and APMA activated MMP-2, where the differences in N- and C-ter-
minal amino acid residues had an effect on the Km value for the substrate [62].
The obtained Km value for MMP-14 was 6.9 ± 0.9 μM. The Km values obtained for MMP-9
and MMP-14 are similar to our previous Km values (4 ± 1 μM and 6 ± 1 μM) determined
under almost identical conditions, with the exception that the assay in our previous study also
contained 5% DMSO [67].
With the bacterial MPs, the quenched fluorescence substrate Mca-RPPGFSAFK(Dnp)-OH
was used. The obtained Km values for auerolysin, thermolysin and pseudolysin were
47 ± 41 μM, 6 ± 1 μM and 24 ± 8 μM, respectively. For auerolysin and pseudolysin, the Km val-
ues are far above the highest concentration that could be used in the assay due to quenching at
concentrations higher than 10 μM. In spite of the low precision of the obtained Km values for
auerolysin and pseudolysin, it can be concluded that the substrate concentration of 5.0 μM
and 4.0 μM used in the inhibition experiments is far lower than the Km value, and hence the
obtained IC50 and Kiapp values are close to the real Ki values.
Ki determination
To be able to compare the binding strength of different inhibitors for a given enzyme and of a
given inhibitor for different enzymes, it is important that the reported Ki values are obtained
under the same conditions and with the same methods. For tight binding inhibitors, it is nec-
essary to know the amount of active enzyme in the assay in order to obtain a correct Ki value.
As the two inhibitory compounds studied here contain a strong zinc binding residue, the
hydroxamate group, the two compounds are believed to be competitive inhibitors. To assure
that the obtained Ki values for the two compounds are as correct as possible and competitive
with the substrate, we have varied the concentration of the inhibitors in a series of experi-
ments. Two different concentrations of enzyme have been used, and in some cases also two
different substrate concentrations. We have compared the obtained results from two plotting
and estimation methods, which determine both the concentration of active enzyme ([E]) in
the assay and the Ki value. One method is using the Morrison equation [71] (Eq 2 in the Mate-
rials and Methods section) to fit the results to a plot vi/v0 vs [I], while the other is the Hender-
son plot [72] (Eq 3 in the Materials and Methods section) which is based on a linearized form
of the Morrison equation.
Ki MMP-14. Galardin (Gm6001) inhibits the MMP-14 (catalytic domain) with a reported
IC50 value of 13.4 nM [60], while the IC50 value is not reported for compound 1b. Fig 3A
shows a typical dose response plot (vi/v0 vs [Gm6001]) using two different enzyme concentra-
tions and Fig 3B a typical Henderson plot where one experiment contained twice as high con-
centration of both MMP-14 and substrate as the other experiment. In the Henderson plot the
concentration of MMP-14 in the assay can be directly determined from the regression lines
crossing of the y-axis. Furthermore, the slope in a Henderson plot gives an apparent Ki (Kiapp)
value. For a competitive inhibitor, Kiapp equals Ki(1+[S]/Km) and hence, the slope increases
with increasing substrate concentrations. As expected, this is the case for the galardin inhibi-
tion of MMP-14 (Fig 3B). Table 1 shows the obtained average Ki value from the different Hen-
derson plots. Although there were some differences in the results obtained from the
Henderson plot and the Morrison equation for an individual experiment (S1 Table and Fig 3),
the average Ki value for galardin was the same, 0.87 nM.
The inhibitory effects of compound 1b on MMP-14 are shown in Fig 3C and 3D. Although
the Ki values obtained from the Morrison equation are slightly higher than the values obtained
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Fig 3. Inhibition of MMP-14 by galardin (A, B) and compound 1b (C, D). The inhibition constant Ki and [MMP-14] in assay
were obtained from dose response plots vi/v0 vs [I] using the Morrison Eq (2) (A, C) and Henderson plots (B, D). In all plots, [MMP-
14] was twice as high for experiments labelled (□) as for those labelled (●). The [S] is 5.0 μM except in the experiment in (B) labelled
(□) where it is 10.0 μM. Shown in the figures is also the obtained Ki and [E] values (mean ± SD), in addition to the regression
coefficient r2 and the number of individual assays (N) for each curve.
https://doi.org/10.1371/journal.pone.0200237.g003
Table 1. Inhibitory activity of galardin and compound 1b against human and bacterial metalloproteases.
Protease Ki (nM)
Galardin 1b
MMP-14 0.870 ± 0.070 (5) 0.090 ± 0.020 (4)
rMMP-9(A) 0.051 ± 0.003 (5) 0.011 ± 0.001 (2)
rMMP-9(T) 0.069 ± 0.001 (5) N.D.a
rMMP-9(M3) 0.063 ± 0.008 (3) N.D.
MMP-9(T) 0.067 ± 0.006 (4) 0.006 ± 0.000 (2)
Auerolysin 452 ± 35 (1)b N.I.c
Thermolysin 20d N.I.
Pseudolysin 20d N.I.
The Ki values were obtained through Henderson plots as described in materials and methods. Presented is the Ki ± S.E.M. and in parenthesis the number of independent
individual experiments that has given rise to the presented values. The results shown are for recombinant human MMP-14 catalytic domain, recombinant human
MMP-9 activated with APMA (rMMP-9(A)), magnetic trypsin beads (rMMP-9 (T)), MMP-3 (rMMP-9(M3), trypsin activated human MMP-9 isolated from THP-1
cells (MMP-9 (T)), auerolysin, thermolysin and pseudolysin.
aN.D., not done;
bValues from dose response plot using Eq (1) in methods;
cN.I., no inhibition up to 100 μM of inhibitor;
dValues from Grobelny D et al. [58].
https://doi.org/10.1371/journal.pone.0200237.t001
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from the Henderson plots of the same experiment (S2 Table), it can be concluded that com-
pound 1b is a significantly stronger MMP-14 binder than galardin (p<0.001; Table 1).
Ki MMP-9. Previous works showed that both galardin and compound 1b are tight binding
inhibitors of MMP-9. The obtained IC50 and Ki values for galardin were 0.5 nM and 0.18 nM,
respectively [59, 60] and a Ki value for compound 1b of 0.097 nM [61]. An MMP may be acti-
vated by several different compounds, including various proteases and organo-mercurial com-
pounds like APMA. This often results in removal of non-identical parts from the pro-domain
of the given MMP, giving a different N-terminal residue of the activated forms. Differences in
N-terminal residue of the activated forms may affect both inhibitor binding and degradation of
biological and small chromogenic substrates. Previously we have shown that APMA and trypsin
activated MMP-2 have different capacity to bind TIMP-1 as well as different ability to cleave
both gelatin and the quenched fluorescence substrate Mca-PLGLDpaAR-NH2 [62]. We have
therefore tested the binding of galardin to APMA, MMP-3 and trypsin activated MMP-9 and
compound 1b to both APMA and trypsin activated MMP-9. As shown in Tables 1 and S1,
galardin binds with similar strength to the four forms of activated MMP-9 (0.051–0.069 nM,
Henderson plot; 0.057–0.074 nM, Morrison equation). Furthermore, the Ki values calculated
from the Morrison equation were similar and not statistically different from the values obtained
by the Henderson plot (S1 Table). It was only the Ki value obtained by APMA activated rMMP-
9 that was slightly lower than the values for the other activated forms. Disregarding this slight
difference in binding strength, it can be concluded that the difference in N- and C-terminal
amino acid residues in the different activated rMMP-9 species, the presence of the HPX-domain
and small amounts of TIMP-1 (MMP-9) as well as differences in O-glycosylation of the hinge
region (rMMP-9 vs MMP-9) have no significant effect on the enzyme’s affinity for galardin.
Compound 1b binds significantly stronger to both APMA and trypsin activated MMP-9
than galardin (p<0.003; Tables 1, S1 and S2). Furthermore, the Ki values of compound 1b cal-
culated from the Morrison equation (0.016 ± 0.001; 0.008 ± 0.003) was not statistically differ-
ent from the values obtained from the Henderson plots (0.011 ± 0.001; 0.006 ± 0.002) (S2
Table). Furthermore, the difference in Ki for compound 1b between rMMP-9 and MMP-9 was
not statistically significant (Tables 1 and S2).
Ki bacterial metalloproteases. Previous studies showed that galardin is a strong inhibitor
of thermolysin and pseudolysin (Table 1) [58]. In initial scanning experiments of various
inhibitors in our laboratory, galardin was used as a control compound. The obtained Ki values
(data not shown) were similar to those obtained by Grobelny et al [58]. Galardin was also a
strong inhibitor of auerolysin with a Ki value much larger than the 3.6 nM of enzyme used in
the assay. The line in the Henderson plot crossed at origo. The Kiapp value from the slope of
the curve was 0.50 ± 0.06 μM (r2 = 0.84; N = 16), giving a Ki value of 0.45 ± 0.05 μM. A dose
response plot vi/v0 vs [galardin] using Eq (1) in the Materials and Methods section resulted in
an IC50 value of 0.50 ± 0.04 μM (r2 = 0.96; N = 18) giving a Ki value of 0.45 μM (Table 1). Thus,
the binding of galardin to auerolysin is about 25 times weaker than the binding to thermolysin
and pseudolysin.
Notable, up to the highest concentration tested of compound 1b (100 μM), no inhibitory
effect of the three bacterial MPs was detected (Table 1).
Docking and molecular modelling
In order to elucidate the structural reasons for the differences in binding affinity for the
studied MPs, we have examined the binding modes of galardin and 1b by docking. Further-
more, it was suggested that the NHOH group of a hydroxamate compound may lose its pro-
ton at or close to the physiological pH and generate a negatively charged group (NHO-)
Inhibition of human and bacterial metalloproteases
PLOS ONE | https://doi.org/10.1371/journal.pone.0200237 August 3, 2018 14 / 28
[82]. Protonation/deprotonation of the NHO(H) moiety may influence the zinc binding
properties of hydroxamate compounds, and therefore, 1b and galardin were docked both
with protonated and deprotonated NHO(H) moiety. When available, the compounds were
docked into several structures of the enzyme. In that way, target structural flexibility to
some extent was taken into account in the docking process. The docking studies indicated
that the protonated and deprotonated inhibitors had almost similar binding modes at the
active sites. Further, the docking showed that the protonated galardin and 1b had better
docking scores than the deprotonated forms for all enzymes, which is contradictory to a
previous docking study of other hydroxamates for the MMP-9, indicating that the deproto-
nated hydroxamates in general scored better than the protonated [83].
MMP-9
Four MMP-9 complexes from the PDB database were used for docking of both protonated
and deprotonated variants of galardin and 1b. The best scoring values were obtained with the
5cuh (PDB ID) structure. This structure is obtained from a truncated recombinant MMP-9
variant, that is lacking the pro, hinge and C-terminal HPX domains in addition to the FnII
module in the catalytic site, and the PDB file is numbered from amino acids G106 to G269.
The N-terminal of this recombinant variant is starting at the 106-GFQT segment. The G resi-
due is not present in the natural variant [25, 27] and in trypsin and MMP-3 activated MMP-9
the N-terminal is 107-FQT [32]. In the full-length enzyme, the 175 amino acid long FnII mod-
ule is present between amino acids V216 and G217 and we therefore used the numbering
given in the Merops data base [25] for the amino acids. The X-ray structure of the human
proMMP-9 has been resolved at 2.5 Å resolution (PDB id: 1L6J). The structure includes the
pro-domain, the catalytic domain and the FnII module. The docking was performed into X-
ray complexes with small molecular inhibitors that were used to define the binding region of
the inhibitors during docking. A grid map that included all amino acids within 5Å of the co-
crystallized inhibitor were used in the docking. The FnII module may influence inhibitor bind-
ing, but Fig 4 indicates that the FnII domain is located far from the binding site of small molec-
ular inhibitors, and that the grid map used for docking should not be influenced by the
presence of the FnII module. The lack of FnII module in the 5cuh structure should therefore
not affect the docking of the molecules in the present study.
For protonated compound 1b, both the oxygens on the NHO(H) and CO groups of the
hydroxamate moiety binds to the catalytic zinc (Fig 5). In addition, the hydroxamate forms
hydrogen bonds between the hydroxyl hydrogen of the NHO(H) moiety and the side chain of
E402, while the nitrogen hydrogen of the NHO(H) moiety forms a hydrogen bond with the
backbone CO of A189. The heterocyclic ring with its three OH-groups points into the opening
of the active site cavity and appears not to have direct interactions with residues of the enzyme.
One of the oxygens of the SO2 group forms a hydrogen bond with the backbone NH of L188.
The diphenyl ether moiety is located within the S´1-subpocket (Fig 6) having interactions with
the side chains of L188, L397, V398, H401, Y423 and T426 (Figs 5 and 6). Compound 1b also has
van-der Waals interactions with many main chain residues including H401, M422 and R424. In
summary, in addition to large van-der Waals interactions, compound 1b forms 3 hydrogen
bonds with the enzyme and 2 ionic interactions with the catalytic zinc ion. The de-protonated
form of compound 1b overlapped with the protonated form and the main difference was that
the de-protonated variant lacked the hydrogen bond to the E402 side chain (not shown).
The binding mode of galardin to MMP-9 was similar to that of compound 1b (Fig 5). The
CO and NHO(H) moieties interact with the zinc, E402 and A189 similarly to compound 1b.
The 4-methylpentanoyl moiety in galardin was located in the S´1-subpocket, but not as deep
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into the pocket and with less interaction than the diphenyl ether of compound 1b (Fig 6). The
main interactions of this hydrophobic moiety of galardin are with the side chains of H401,
V398, P421 and Y423 (Fig 5). The oxygen of the CO neighbour of the 4-methylpentanoyl moi-
ety and the oxygen on the tryptophan methylamide form hydrogen bonds with the main chain
NH of L188 and Y423, respectively. The tryptophan moiety points into the opening of the
active site cavity and appears to have no direct interactions with the enzyme. The docking indi-
cates that both protonated 1b and galardin forms two ionic interactions with the zinc, and
three hydrogen bonds with the enzyme. The main difference is that the diphenyl ether moiety
of compound 1b penetrates deeper into the S´1-subpocket than the 4-methylpentanoyl moiety
of galardin (Fig 6). This appears to be the main explanation for the approximately 5 to 10
times stronger interaction of MMP-9 with compound 1b than with galardin.
MMP-14
The docking indicated that compound 1b and galardin bind MMP-14 in similar binding
modes as for MMP-9 (Fig 5). The compounds were docked using two different approaches to
Fig 4. Structural superimposition (backbone) of the 5cuh and the 1l6j x-ray structures of MMP-9. The 1l6j structure contains the FnII
domains (yellow) and the catalytic domain (green), while the 5cuh only contains the catalytic domain (blue). The pro-domain has been deleted
from 1l6j, such that the sequence starts at F107. The co-crystallized hydroxamate inhibitor LT4 of the 5cuh in red, while the catalytic zinc and
the coordinating histidines are in grey. The position of the co-crystallized inhibitor was used to define the docking grid during docking of
galardin and compound 1b, and the figure shows that the docking into a structure lacking the FnII domains (5cuh) should not affect the
docking results.
https://doi.org/10.1371/journal.pone.0200237.g004
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define the binding pocket (ICM pocket finder and superimposing with a MMP-9 inhibitor
complex), and both approaches gave similar results. Both protonated and un-protonated com-
pounds had quite similar binding modes, however, with some differences.
Protonated 1b formed more hydrogen bonds with the enzyme than deprotonated 1b and
had better scoring values. In the highest scored binding mode of compound 1b the two oxygen
atoms in the CONHO(H) moiety formed strong interactions with the catalytic zinc. However,
due to protonation, the position of the CONHOH is slightly disturbed compared with the
deprotonated counterpart, such that the hydroxyl hydrogen of the NHOH forms a hydrogen
bond with the side chain of E240, while NH forms a hydrogen bond with the main chain CO
of A200 (Fig 5). Such hydrogen bonds are not observed for the deprotonated 1b. The three
OH-groups of the heterocyclic ring point into the opening of the active site cavity without
direct interactions with the enzyme. The SO2 group of protonated 1b forms two hydrogen
bonds with the main chain NH of residues A200 and L199 (Fig 5), while the SO2 of the depro-
tonated 1b forms a hydrogen bond with the backbone NH of A200, only. The diphenyl ether
moiety is filling up large parts of the S´1-subpocket as seen for MMP-9 (Fig 6), having interac-
tions with the side chains of L199, L235, V236, H239, I256, P259 and Y261. The ether oxygen
is close to the Nd1 atom of H239. One of the main reasons for the slightly weaker binding of
compound 1b to MMP-14 than to MMP-9 seems to be that the size of the S´1-subpocket is
larger in MMP-9 (based on calculations by ICM pocket finder) and hence allows for more free-
dom of the ligand to obtain optimal interactions.
Galardin binds MMP-14 very similar to compound 1b. The hydroxamate forms two ionic
interactions with the catalytic zinc ion, one through the carbonyl oxygen and the other through
the oxygen at the NHO(H) group (Fig 5). The hydroxyl hydrogen of the protonated NHO(H)
moiety has a hydrogen bond with the side chain of E240. The nitrogen proton at NHO(H)
forms a hydrogen bond with the CO of A200. The 4-methylpentanoyl moiety was located in the
entrance of S´1-subpocket and interacted with the side chains of H239, Y261(Me), L199(cd1)
and V236. The amide neighbour of the 4-methylpentanoyl moiety forms two hydrogen bonds,
one between the CO oxygen and main chain NH of L199, and the other between the NH and
the CO on P259. The methylamide moiety also forms two hydrogen bonds to the main chain of
the enzyme, one between the CO group and the NH of Y261 and the other between the NH
moiety and the CO of G197. The tryptophan moiety points into the opening of the active site
cavity having minimal interactions with the enzyme. The most likely explanation for the 10
times stronger interaction of compound 1b with the enzyme compared to the interaction with
galardin is that the diphenyl ether moiety in the former compound has a larger interaction sur-
face with the S´1-subpocket than the 4-methylpentanoyl moiety of galardin.
Bacterial metalloproteases
The binding studies indicated that galardin binds quite strongly to thermolysin and pseudoly-
sin and somewhat weaker to aeurolysin, while inhibition of these enzyme by compound 1b
was not observed. These results were also confirmed by the docking studies. Galardin fits into
the binding pocket of these enzymes with ionic interactions between the oxygen atoms of the
CONHO(H)-moiety and the zinc ion (Fig 7), and with the 4-methylpentanoyl moiety into S´1-
Fig 5. Galardin and compound 1b docked into the catalytic site of MMP-9 and MMP-14. The figure shows close ups of the
active site region with the compound structures (xsticks), secondary structure elements and the most important amino acids for
ligand binding (xsticks) indicated. Colour coding of atoms of amino acids and ligands: oxygen; red, nitrogen; blue, hydrogen;
white, sulphur; yellow, carbon atoms of ligands; yellow, carbon atoms of amino acid side chains; pink, the zinc ion; light blue.
The secondary structures elements are coloured from the N- to the C-terminal such that corresponding secondary elements of
MMP-9 and MMP-14 obtain similar colour.
https://doi.org/10.1371/journal.pone.0200237.g005
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Fig 6. Galardin and compound 1b docked into MMP-9 and galardin docked into pseudolysin. Upper panel: The
backbones of MMP-9 (5cuh) and pseudolysin (3dbk). The volume of the full binding pocket identified by the ICM
Pocketfinder is displayed for both enzymes, with the S’1-subpocket indicated by an arrow. Middle panel: Galardin (red)
and compound 1b (blue) docked into the binding pocket of MMP-9 and galardin (red) docked into pseudolysin. The
panel shows that compounds may enter the S’1-subpocket of MMP-9 in a region between the side chains of Y423 and
L188 on one side and the zinc. The corresponding entrance in pseudolysin is partly hindered by the side chain of R198.
Lower panel: The complex from the middle section rotated 90 degrees and the ligands removed. The panel shows that the
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subpocket (Figs 6 and 7). However, compound 1b, did not fit into the binding site of the bacte-
rial enzymes, and reasonable binding modes were not obtained in any of the bacterial
enzymes. The docking indicates that the diphenyl ether moiety of 1b is too big for a proper fit-
ting into the S´1-subpocket as observed for compound 1b in the MMPs. The S´1-subpocket of
the bacterial enzymes seems much more rigid than that of the MMPs. An important reason for
that is an arginine (corresponding to R198 of pseudolysin), which is located at the end of a β-
strand at the border between the S´1- and S´2-subpockets and is pointing into the binding site.
This arginine interacts with galardin, but does not hinder the smaller 4-methylpentanoyl moi-
ety of galardin to enter the S´1-subpocket (Figs 6 and 7), while the diphenyl ether moiety of 1b
is hindered. However, the arginine hinders galardin to penetrate deeply into the pocket. The
corresponding region of the studied MMPs constitutes a structurally more flexible loop region
(methionine loop) that more easily can adopt to the inhibitor structure.
For thermolysin, the binding mode of protonated and deprotonated galardin were similar.
The best scoring was obtained with the X-ray structure 5dpe (PDB ID). The CONHO(H)-moi-
ety forms two ionic interactions with the zinc (Fig 7). The NH group of the hydroxamate is
hydrogen bonded with E143 (corresponding to E402 in MMP-9 and E240 in MMP-14), while
the CO group is also hydrogen bonded with the side chain of H231 (NH in the ring). The
4-methylpentanoyl was located in the S´1-subpocket, while the CO oxygen next to the
4-methylpentanoyl formed two hydrogen bonds with the side chain of R203 (Fig 7). Both the
CO and the NH of the tryptophan methylamide are both engaged in hydrogen bonds with the
side chain of N112. The NH of the tryptophan ring forms a hydrogen bond with the CO at the
backbone of N111.
Most of the interactions of galardin with thermoysin are similar to those in pseudolysin
(Fig 7). The amino acids corresponding to E143, H231, R203, N111, and N112 are conserved
between the enzymes. The only differences between the highest scored binding mode in ther-
molysin and pseudolysin was that the NH of the CONHO(H)-moiety was located a bit more
distantly from E141 (corresponding to E143 in thermolysin), and that H223 (corresponding to
H231 in thermolysin) did not form a hydrogen bond with the CO of the hydroxamate.
The binding mode of galardin with auerolysin (Fig 7) is very similar to the binding modes
in thermolysin and pseudolysin, however, there are some differences. Protonated and deproto-
nated galardin have similar binding modes, but protonated galardin scores better than depro-
tonated. The CONHO(H)-moiety forms two ionic interactions with zinc, while the protonated
OH of the hydroxamate has a hydrogen bond with the side chain of E145 (corresponding to
E143 in thermolysin and E141 in pseudolysin). The NH group of the hydroxamate has a
hydrogen bond to the backbone CO of A115. The 4-methylpentanoyl is pointing into the S´1-
subpocket, while the CO oxygen next to the 4-methylpentanoyl forms a hydrogen bond with
the side chain of R200 (corresponding to R203 in thermolysin and R198 in pseudolysin). How-
ever, the CO and the NH of the tryptophan methylamide are not involved in hydrogen bond-
ing with the enzymes, which may explain the lower binding affinity of galardin for aeurolysin
than for thermolysin and pseudolysin.
Conclusions
Activation of the rproMMP-9 resulted in a largely truncated form in all scenarios, lacking
most of or the entire HPX-domain but appearing to contain the entire O-glycosylated hinge
region. The main difference between the three activated variants of rMMP-9 seems to be in the
side chains of L188 and Y423 are located close to each other and hinder the entrance into the S’1-subpocket from the
region above the zinc, while the corresponding region in pseudolysin is wider (side chains of N112 and L197).
https://doi.org/10.1371/journal.pone.0200237.g006
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Fig 7. Galardin docked into the catalytic site of thermolysin, pseudolysin and auerolysin. The figure shows close
ups of the active site region with the compound structures (xsticks), secondary structure elements and the most
important amino acids for ligand binding (xsticks) indicated. Colour coding of atoms of amino acids and ligands:
Inhibition of human and bacterial metalloproteases
PLOS ONE | https://doi.org/10.1371/journal.pone.0200237 August 3, 2018 21 / 28
N-terminal region. The trypsin and MMP-3 activated forms have F107 and the APMA acti-
vated form M94 as the N-terminal residue. The major form of the trypsin activated MMP-9
from THP-1 cells retained its C-terminal HPX-domain due to the presence of some TIMP-1 in
the purified enzyme, with F107 as its N-terminal residue. In spite of all these differences, these
four differently processed and activated forms had an almost identical Km value for the
quenched fluorescence substrate Mca-PLGLDpaAR-NH2 and Ki values for galardin and com-
pound 1b. This suggests that it is possible to compare the average binding strength of the two
compounds to each other as well as between the enzymes.
The previously presented binding strength of galardin to MMP-9 and MMP-14 and com-
pound 1b to MMP-9 appears to be slightly under-estimated compared to the results of the
present study. The reason is most likely that these compounds previously have been tested in a
series of a large number of compounds against several MPs, and hence detailed kinetic con-
stants were not obtained. An exception is the study of Pourmotabbed et al [59] who studied
the binding of galardin to wild-type and mutated un-glycosylated human MMP-9 produced in
E coli. Both our study and the previous studies show that galardin has a stronger interaction
with MMP-9 than with MMP-14. Our study also shows that compound 1b binds stronger to
MMP-9 than to MMP-14 (p<0.002; Tables 1 and S2). An important difference between these
two compounds is that compound 1b binds stronger than galardin to the two human MMPs
(Tables 1, S1 and S2), and the docking studies indicated that this could be explained by that
the diphenyl ether moiety of compound 1b has a larger interaction surface with the S´1-sub-
pocket than the 4-methylpentanoyl moiety in galardin. Our studies show that galardin binds
quite strongly to all the bacterial MPs, but weaker than to the MMPs, while compound 1b did
not bind the bacterial MPs at all. The size and structural rigidity of the S´1-subpocket explains
why the MMPs more easily adopt to the structure of the inhibitors than do the bacterial MPs.
The docking indicated that the diphenyl ether moiety of compound 1b could not fit into the S
´1-subpocket of thermolysin, pseudolysin and auerolysin as observed for the MMPs, while the
smaller 4-methylpentanoyl moiety of galardin could enter the S´1-subpocket. The entrance
from the top of the S´1-subpocket of the MMPs is quite narrow due to side chain of Y423 and
L188 (MMP-9 numbering) as previously explained [56, 57]. However, both galardin and com-
pound 1b may enter the pocket between the zinc atom and H401 (MMP-9 numbering) on one
side and the tyrosine and leucine side chains in the other side. The pocket is also structurally
quite flexible since the methionine loop constitutes a large part of the pocket, and therefore the
pocket may adopt quite big ligand entities. The entrance from the top of the S´1-subpocket of
the bacterial enzymes is wider than that of the MMPs. However, an arginine side chain located
at the border between the S´1 and S´2-subpockets is pointing into the binding site and interacts
with galardin, and hinders the compound to penetrate deeply into the subpocket (Fig 6). This
arginine is located at a rigid β strand, while the corresponding region of the MMPs is in the
methionine loop. The docking also indicated that the reason for stronger binding of galardin
to thermolysin and pseudolysin than to auerolysin could be explained by hydrogen bonding
interactions between the tryptophan methylamide moiety of galardin with two aspargines in
pseudolysin and thermolysin (Fig 7). Such interactions were not seen with auerolysin. The
present study indicates that the size and shape of the ligand structural moiety entering the S´1-
subpocket is an important determinant for selectivity between the studied MMPs and bacterial
MPs. Compounds with less interaction with the S´1- subpocket, but occupy other subpockets
may bind more selectively to the bacterial enzymes than to the MMPs.
oxygen; red, nitrogen; blue, hydrogen; white, carbon atoms of ligands; yellow, carbon atoms of amino acid side chains;
grey, the zinc ion; light blue.
https://doi.org/10.1371/journal.pone.0200237.g007
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Supporting information
S1 Fig. Activation of full length recombinant human proMMP-9 with MMP-3(catalytic
domain). (A) Twenty µL of 4.6 µM proMMP-9 was mixed with 20 µL of 0.05 µM MMP-3 at
37˚C. At different time points either 0.5 µL (up to 30 min) or 0.25 µL (from 40 min) of activa-
tion mixture was added to 99 µL of 10 µM substrate (in assay buffer) and the enzyme activity
(initial rate) was determined as described in methods. (B) At the same time points as in (A), 0.5
µL of activation mixture was mixed with 19.5 µL of 10 mM EDTA (in assay buffer). This mix-
ture was further diluted (12.5 times) and mixed with sample buffer and applied to real-time gel-
atin zymography as described in methods. The molecular size standards used were proMMP-9
purified from THP-1 cells (proMMP-9), recombinant human full length proMMP-9 purified
(rproMMP-9) from sf9 cells, the 37 kDa catalytic domain of MMP-9 (Std 3) and a mixture of
proMMP-9 from THP-1 cells and proMMP-2 from human skin fibroblasts (St 2).
(PDF)
S1 Table. Inhibitory constant Ki of galardin against human metalloproteases. The Ki ± s.d.
values for each experiment were obtained through both Henderson plots and the Morrison
equation as described in materials and methods. Shown is also the average x  ± S.E.M. value for
each enzyme and plot. The results shown are for recombinant human MMP-14 catalytic
domain, recombinant human MMP-9 activated with APMA (rMMP-9(A)), magnetic trypsin
beads (rMMP-9 (T)), MMP-3 (rMMP-9(M3) and trypsin activated human MMP-9 isolated
from THP-1 cells (MMP-9 (T)).
(PDF)
S2 Table. Inhibitory constant Ki of compound 1b against human metalloproteases. The Ki
± s.d. values for each experiment were obtained through both Henderson plots and the Morri-
son equation as described in materials and methods. The average x  ± S.E.M. values for each
enzyme and plot are also shown. The results shown are for recombinant human MMP-14 cata-
lytic domain, recombinant human MMP-9 activated with APMA (rMMP-9(A)) and trypsin
activated human MMP-9 isolated from THP-1 cells (MMP-9(T)).
(PDF)
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